Search reports.
Alpha 1 Antitrypsin Deficiency Treatment Market Share [2031]
Get free sample report Request for Customiztion Buy Now

Alpha 1 Antitrypsin Deficiency Treatment Market Share [2031]

Segments - Alpha-1 Antitrypsin Deficiency Treatment Market by Treatment Types (Augmentation Therapy, Bronchodilators, Corticosteroids, Oxygen Therapy, and Others), Route of Administration (Parental, Inhalation, and Oral), End-users (Hospitals, Specialty Clinics, and Others), and Regions (Asia Pacific, North America, Europe, Latin America, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 - 2031

https://growthmarketreports.com/raksha
Author : Raksha Sharma
https://growthmarketreports.com/Vaibhav
Fact-checked by : V. Chandola
https://growthmarketreports.com/Vishal
Editor : Vishal Golekar

Upcoming | Report ID :HC-3190 | 4.2 Rating | 73 Reviews | 202 Pages | Format : PDF Excel PPT

Report Description


Alpha-1 Antitrypsin Deficiency Treatment Market Outlook 2031:

The Alpha-1 antitrypsin Deficiency Treatment Market size was valued at USD 1.49 Billion in 2022 and is projected to reach USD 3.78 Billion by 2031, expanding at a CAGR of 10.9% during the forecast period 2023 - 2031. Alpha-1 antitrypsin deficiency or AAT deficiency, is a genetic disorder characterized by a lack of AAT protein in the body. It is essential for the lungs and liver to defend themselves against the harmful effects of other proteins.

The deficiency of AAT can develop liver cirrhosis, chronic obstructive pulmonary disease (COPD), or emphysema. Tests such as genetics and blood tests can diagnose this disease. Medicines such as bronchodilators and corticosteroids, which can be injected intravenously or inhaled, are frequently used for treatment methods such as augmentation therapy, pulmonary rehabilitation, and oxygen therapy.

Alpha-1 Antitrypsin Deficiency Treatment Market Outlook

  • Increasing improvement in the diagnosis of alpha1-antitrypsin deficiency is estimated to boost the growth of the market.
  • Various technological advancements in the diagnostic methods and the development of innovative processes for the production & purification of AAT are acting as growth-inducing factors for the market.
  • High prevalence of chronic respiratory diseases across the world is the major driver for the growth of the market.
  • Widespread adoption of augmentation therapy is providing a thrust to the market growth.
  • Increasing cost of drugs can create challenges for the market growth.
  • Stringent regulations along with less availability of plasma fractionation capacity can restrain the growth of the market.
  • Increasing demand for deficiency treatment, improving economic scenario, increasing awareness regarding alpha1-antitrypsin deficiency, surging investment for the development of advanced and technical products are some of the factors that can accelerate the growth.
  • The PlasmaTech SDF (salt diafiltration) process is a plasma-based platform was introduced for mass production of orphan protein therapeutics such as alpha-1 antitrypsin Thus, such innovation can create lucrative opportunities for the industry players.

Scope of Alpha-1 Antitrypsin Deficiency Treatment Market Report

The report on alpha-1 antitrypsin deficiency treatment market includes an assessment of the market, size, share, trends, segments, and regional markets. Overview and dynamics have been included in the report.

Attributes

Details

Report Title

Alpha-1 Antitrypsin Deficiency Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast

Base Year

2022

Historic Data

2016 & 2021

Forecast Period

2023–2031

Segmentation

Treatment Types (Augmentation Therapy, Bronchodilators, Corticosteroids, Oxygen Therapy, and Others), Route of Administration (Parental, Inhalation, and Oral), End-users (Hospitals, Specialty Clinics, and Others)

Regional Scope

Asia Pacific, North America, Europe, Latin America, and Middle East & Africa

Report Coverage

Market scope, analysis, share, competitive analysis, growth facts, restraints, opportunities, and revenue forecast

Key Players Covered in the Report

Grifols, S.A., Kamada Pharmaceuticals., CSL, Arrowhead Pharmaceuticals, Inc., CHIESI Farmaceutici S.p.A., AstraZeneca, Henry Schein, Inc., Healthy Life Pharma Private Limited., Hovione, Switzer Life science Pvt. Ltd., Cyndea Pharma, Anuh Pharma Ltd., Cipla Inc., Pfizer Inc., Anantco Enterprises Pvt. Ltd.

Alpha-1 Antitrypsin Deficiency Treatment Market Segment Insights

Augmentation therapy segment is projected to hold significant market share

In the terms of treatment types, the market can be divided into augmentation therapy, bronchodilators, corticosteroids, oxygen therapy and others. The augmentation therapy segment accounted for a major market share in 2020, and is expected to continue to grow at a robust rate during the forecast period. This is due to high acceptance of the therapy in developed regions such as the US and Europe.

Alpha-1 Antitrypsin Deficiency Treatment Market Treatments Types

Inhalation segment is anticipated to account for a substantial share

Based on route of administration, the alpha-1 antitrypsin deficiency treatment market can be segregated into parental, inhalation and oral. The inhalation segment is estimated to hold a substantial market during the forecast period owing to increasing focus on R&D for developing inhalation formulation of existing alpha-1 antitrypsin.

Hospital segment accounted for a major market share in 2020

On the basis of end-users, the market can be divided into hospitals, specialty clinics, and others. The hospitals segment dominated the global market in 2020 due to rising patients of COPD and presence of favourable reimbursement programs in developed and emerging countries.

Alpha-1 Antitrypsin Deficiency Treatment Market End Users

North America to dominates the market

In terms of regions, the alpha-1 antitrypsin deficiency treatment market can be categorized as Asia Pacific, North America, Europe, Latin America, and the Middle East & Africa.

North America is estimated to dominate the market in 2020 due to growing prevalence of alpha1-antitrypsin deficiency along with increasing healthcare expenditure, while the market in Asia Pacific is expected to grow at a robust CAGR during the forecast period due to increasing initiatives by the government to control genetic disorders and improvement in diagnostics techniques.

Alpha-1 Antitrypsin Deficiency Treatment Market Region

Segments

By Treatment Types

  • Augmentation Therapy
  • Bronchodilators
  • Corticosteroids
  • Oxygen Therapy
  • Others

By Route of Administration

  • Parental
  • Inhalation
  • Oral

By End-users

  • Hospitals
  • Specialty Clinics
  • Others

By Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

By Key Players

  • Grifols, S.A.
  • Kamada Pharmaceuticals.
  • CSL
  • Arrowhead Pharmaceuticals, Inc.
  • CHIESI Farmaceutici S.p.A.
  • AstraZeneca
  • Henry Schein, Inc.
  • Healthy Life Pharma Private Limited.
  • Hovione
  • Switzer Life science Pvt. Ltd.
  • Cyndea Pharma
  • Anuh Pharma Ltd.
  • Cipla Inc.
  • Pfizer Inc.
  • Anantco Enterprises Pvt. Ltd.

Competitive Landscape

Key players in the alpha-1 antitrypsin deficiency treatment market are Grifols, S.A., Kamada Pharmaceuticals., CSL, Arrowhead Pharmaceuticals, Inc., CHIESI Farmaceutici S.p.A., AstraZeneca, Henry Schein, Inc., Healthy Life Pharma Private Limited.,

Hovione, Switzer Life science Pvt. Ltd., Cyndea Pharma, Anuh Pharma Ltd., Cipla Inc., Pfizer Inc., Anantco Enterprises Pvt. Ltd., among other domestic and global players.These players engage in mergers & acquisitions, collaborations, agreements, and partnerships to strengthen their geographical presence.

Alpha-1 Antitrypsin Deficiency Treatment Market Key Players

Table Of Content

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Alpha-1 Antitrypsin Deficiency Treatment Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Alpha-1 Antitrypsin Deficiency Treatment Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Alpha-1 Antitrypsin Deficiency Treatment Market - Supply Chain
  4.5. Global Alpha-1 Antitrypsin Deficiency Treatment Market Forecast
     4.5.1. Alpha-1 Antitrypsin Deficiency Treatment Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Alpha-1 Antitrypsin Deficiency Treatment Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Alpha-1 Antitrypsin Deficiency Treatment Market Absolute $ Opportunity
5. Global Alpha-1 Antitrypsin Deficiency Treatment Market Analysis and Forecast by Types
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Types
     5.2.2. Y-o-Y Growth Projections by Types
  5.3. Alpha-1 Antitrypsin Deficiency Treatment Market Size and Volume Forecast by Types
     5.3.1. Augmentation Therapy
     5.3.2. Bronchodilators
     5.3.3. Corticosteroids
     5.3.4. Oxygen Therapy
     5.3.5. Others
  5.4. Absolute $ Opportunity Assessment by Types
  5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Alpha-1 Antitrypsin Deficiency Treatment Market Analysis and Forecast by Region
  6.1. Market Trends
  6.2. Introduction
     6.2.1. Basis Point Share (BPS) Analysis by Region
     6.2.2. Y-o-Y Growth Projections by Region
  6.3. Alpha-1 Antitrypsin Deficiency Treatment Market Size and Volume Forecast by Region
     6.3.1. North America
     6.3.2. Latin America
     6.3.3. Europe
     6.3.4. Asia Pacific
     6.3.5. Middle East and Africa (MEA)
  6.4. Absolute $ Opportunity Assessment by Region
  6.5. Market Attractiveness/Growth Potential Analysis by Region
  6.6. Global Alpha-1 Antitrypsin Deficiency Treatment Demand Share Forecast, 2019-2026
7. North America Alpha-1 Antitrypsin Deficiency Treatment Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
  7.2. North America Alpha-1 Antitrypsin Deficiency Treatment Market Size and Volume Forecast by Country
     7.2.1. U.S.
     7.2.2. Canada
  7.3. Absolute $ Opportunity Assessment by Country
  7.4. North America Alpha-1 Antitrypsin Deficiency Treatment Market Size and Volume Forecast by Types
     7.4.1. Augmentation Therapy
     7.4.2. Bronchodilators
     7.4.3. Corticosteroids
     7.4.4. Oxygen Therapy
     7.4.5. Others
  7.5. Basis Point Share (BPS) Analysis by Types
  7.6. Y-o-Y Growth Projections by Types
  7.7. Market Attractiveness/Growth Potential Analysis
     7.7.1. By Country
     7.7.2. By Product Type
     7.7.3. By Application
  7.8. North America Alpha-1 Antitrypsin Deficiency Treatment Demand Share Forecast, 2019-2026
8. Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Latin America Average Pricing Analysis
  8.2. Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Size and Volume Forecast by Country
      8.2.1. Brazil
      8.2.2. Mexico
      8.2.3. Rest of Latin America
   8.3. Absolute $ Opportunity Assessment by Country
  8.4. Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Size and Volume Forecast by Types
     8.4.1. Augmentation Therapy
     8.4.2. Bronchodilators
     8.4.3. Corticosteroids
     8.4.4. Oxygen Therapy
     8.4.5. Others
  8.5. Basis Point Share (BPS) Analysis by Types
  8.6. Y-o-Y Growth Projections by Types
  8.7. Market Attractiveness/Growth Potential Analysis
     8.7.1. By Country
     8.7.2. By Product Type
     8.7.3. By Application
  8.8. Latin America Alpha-1 Antitrypsin Deficiency Treatment Demand Share Forecast, 2019-2026
9. Europe Alpha-1 Antitrypsin Deficiency Treatment Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Europe Average Pricing Analysis
  9.2. Europe Alpha-1 Antitrypsin Deficiency Treatment Market Size and Volume Forecast by Country
     9.2.1. Germany
     9.2.2. France
     9.2.3. Italy
     9.2.4. U.K.
     9.2.5. Spain
     9.2.6. Russia
     9.2.7. Rest of Europe
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Europe Alpha-1 Antitrypsin Deficiency Treatment Market Size and Volume Forecast by Types
     9.4.1. Augmentation Therapy
     9.4.2. Bronchodilators
     9.4.3. Corticosteroids
     9.4.4. Oxygen Therapy
     9.4.5. Others
  9.5. Basis Point Share (BPS) Analysis by Types
  9.6. Y-o-Y Growth Projections by Types
  9.7. Market Attractiveness/Growth Potential Analysis
     9.7.1. By Country
     9.7.2. By Product Type
     9.7.3. By Application
  9.8. Europe Alpha-1 Antitrypsin Deficiency Treatment Demand Share Forecast, 2019-2026
10. Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Asia Pacific Average Pricing Analysis
  10.2. Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Size and Volume Forecast by Country
     10.2.1. China
     10.2.2. Japan
     10.2.3. South Korea
     10.2.4. India
     10.2.5. Australia
     10.2.6. Rest of Asia Pacific (APAC)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Size and Volume Forecast by Types
     10.4.1. Augmentation Therapy
     10.4.2. Bronchodilators
     10.4.3. Corticosteroids
     10.4.4. Oxygen Therapy
     10.4.5. Others
  10.5. Basis Point Share (BPS) Analysis by Types
  10.6. Y-o-Y Growth Projections by Types
  10.7. Market Attractiveness/Growth Potential Analysis
     10.7.1. By Country
     10.7.2. By Product Type
     10.7.3. By Application
  10.8. Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Demand Share Forecast, 2019-2026
11. Middle East & Africa Alpha-1 Antitrypsin Deficiency Treatment Market Analysis and Forecast
  11.1. Introduction
     11.1.1. Basis Point Share (BPS) Analysis by Country
     11.1.2. Y-o-Y Growth Projections by Country
     11.1.3. Middle East & Africa Average Pricing Analysis
  11.2. Middle East & Africa Alpha-1 Antitrypsin Deficiency Treatment Market Size and Volume Forecast by Country
     11.2.1. Saudi Arabia
     11.2.2. South Africa
     11.2.3. UAE
     11.2.4. Rest of Middle East & Africa (MEA)
  11.3. Absolute $ Opportunity Assessment by Country
  11.4. Middle East & Africa Alpha-1 Antitrypsin Deficiency Treatment Market Size and Volume Forecast by Types
     11.4.1. Augmentation Therapy
     11.4.2. Bronchodilators
     11.4.3. Corticosteroids
     11.4.4. Oxygen Therapy
     11.4.5. Others
  11.5. Basis Point Share (BPS) Analysis by Types
  11.6. Y-o-Y Growth Projections by Types
  11.7. Market Attractiveness/Growth Potential Analysis
     11.7.1. By Country
     11.7.2. By Product Type
     11.7.3. By Application
  11.8. Middle East & Africa Alpha-1 Antitrypsin Deficiency Treatment Demand Share Forecast, 2019-2026
12. Competition Landscape
  12.1. Global Alpha-1 Antitrypsin Deficiency Treatment Market: Market Share Analysis
  12.2. Alpha-1 Antitrypsin Deficiency Treatment Distributors and Customers
  12.3. Alpha-1 Antitrypsin Deficiency Treatment Market: Competitive Dashboard
  12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     12.4.1. Grifols, S.A.
     12.4.2. Kamada Pharmaceuticals.
     12.4.3. CSL
     12.4.4. Arrowhead Pharmaceuticals, Inc.
     12.4.5. CHIESI Farmaceutici S.p.A.
     12.4.6. AstraZeneca
     12.4.7. Henry Schein, Inc.
     12.4.8. He

Methodology

Our Clients

Dassault Aviation
FedEx Logistics
sinopec
Honda Motor Co. Ltd.
Microsoft
The John Holland Group
General Electric
General Mills